Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Core Insights - Oncotelic Therapeutics, Inc. announced that its investigational intravenous Deciparticle everolimus (Sapu003) will be presented at the 2025 San Antonio Breast Cancer Symposium, highlighting its focus on innovative cancer treatments [1][2] Company Overview - Oncotelic Therapeutics, Inc. was founded to develop transformative medicines for cancer patients, utilizing its PDAOAI platform and expertise in nanomedicines [1] - The company has a history dating back to 1988, originally formed as OXiGENE, Inc., and has undergone several name changes and reincorporations [5][6] Product Development - Sapu003 is a novel formulation of everolimus designed for intravenous use, addressing limitations of oral mTOR inhibitors such as poor bioavailability and dose-limiting toxicity [2] - The ongoing Phase 1 trial of Sapu003 targets hormone receptor-positive (HR⁺)/HER2⁻ metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET) [2] Clinical Trials and Collaborations - The studies related to Sapu003 are conducted in collaboration with Southern Oncology Clinical Research Unit (SOCRU), Ingenu CRO, and Medicilon, focusing on molecular biomarker discovery and pharmacokinetic modeling [4] - Accepted abstracts for presentation at the symposium include research on predictive biomarkers and pharmacokinetic rationale for Sapu003 [4] Market Context - The FDA has previously approved oral everolimus for advanced RCC and pancreatic NET, indicating a market for mTOR inhibitors in oncology [5] - The company aims to leverage its expertise to improve treatment outcomes, particularly for rare pediatric cancers [6][7]